6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine

6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine Featuring the Fenmore Lectureship and the Redlich Lectureship November 3-4, 2017 COURSE DIRECTORS: Monica Mita, MD, MSc Alain C. Mita, MD, MSc Robert Figlin, MD Razelle Kurzrock, MD Lawrence D. Piro, MD FACULTY: David D. Chang, MD, PhD Ezra Cohen, MD Barbara A. Conley, MD Morganna Freeman, DO Mark Goodman, MD, PhD Omid Hamid, MD Andrew E. Hendifar, MD, MPH Edward S. Kim, MD Michael Lill, MD Nan Limvorasak, PharmD Heather McArthur, MD, PhD Ronald B. Natale, MD Edwin M. Posadas, MD Barry Rosenbloom, MD Leanne Sakamoto, PharmD Richard B. Schwab, MD Steven Shiao, MD, PhD Diane Simeone, MD EXPLORE NEW AGENTS IN: Breast Cancer GI Malignancies Head and Neck Cancers T-Cell Therapeutics Harvey Morse Conference Center 90048 In collaboration with For the latest course information and to register, visit cedars-sinai.edu/oncologycme

ACTIVITY INFORMATION COURSE DESCRIPTION AND STATEMENT OF NEED This important educational activity will provide guidance to frontline and oncology clinicians, oncology nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists with the most current information available about new agents in oncology and the translation of the latest research to their patients. The 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine conference will cover drug and treatment updates with a focus on new agents in breast cancer, GI malignancies, and head and neck cancers. The conference will also feature a mini-symposium that will cover various new clinical trials. EDUCATIONAL OBJECTIVES Assess cancer immunotherapy treatments and their application in clinical practice, based on a thorough understanding of how they work, their side effects and indications for use Evaluate emerging clinical data for new agents and evolving strategies for the treatment of breast cancer, and develop individualized treatment plans for patients based upon an evaluation of efficacy and safety Evaluate clinical data and mechanism of action for newly approved drugs for treating cancer Use AJCC or other appropriate staging in clinical practice, including appropriate prognostic indicators and evidence-based national guidelines for treatment planning Recognize and describe the mechanism of action, efficacy and side effects of new treatment options for myeloma List and apply new treatment options for head and neck cancer ACCREDITATION STATEMENT is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. NURSES The California State Board of Registered Nursing accepts courses approved by the ACCME for Category 1 credit as meeting the educational requirements for license renewal. POLICY ON DISCLOSURE It is the policy of to ensure balance, independence, objectivity and scientific rigor in all its educational activities. assesses conflicts of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter s content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations. While endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice. ACKNOWLEDGMENT OF COMMERCIAL SUPPORT Commercial support for this conference is pending. Companies who support this CME activity with educational grants will be acknowledged at the conference. SPECIAL ACKNOWLEDGMENT also wishes to acknowledge the generosity of the Board of Governors Clinical Research Unit for its continuous support. Cedars-Sinai also appreciates the support received from The Fenmore Lectureship and The Redlich Lectureship. The Fenmore Lectureship was initiated in 1978 by Maxwell J. Fenmore to present conferences on oncology. The first annual meeting was held in 1979. The Redlich Lectureship was initiated in 1980 by Freida K. and Max H. Redlich as an endowed lectureship in hematology to honor the outstanding CSMC medical staff and in particular the Division of Hematology/Oncology. In 1981, Mr. Redlich passed away from a rare hematological disorder.

AGENDA FRIDAY, NOVEMBER 3, 2017 CO-CHAIRS: Monica Mita, MD; Ronald Natale, MD 1:30 P.M. Registration 2:00 Value-based therapeutics in oncology Leanne Sakamoto, PharmD; Edwin Posadas, MD 3:00 Drug-drug interactions in oncology Nan Limvorasak, PharmD 3:30 Immuno-oncology: Adverse events management Morganna Freeman, DO 4:00 Integration of immune therapies and radiation oncology Steven Shiao, MD, PhD 4:30 P.M. Reception SATURDAY, NOVEMBER 4, 2017 CO-CHAIRS: Robert Figlin, MD; Razelle Kurzrock, MD 7:30 A.M. Registration 8:10 New drugs approved in 2016 and their mechanism of action Alain Mita, MD 8:40 Q & A MINI-SYMPOSIUM: BIG STUDIES, BIG DATA? 8:50 Precision promise Diane Simeone, MD 9:10 Redlich Lecture: Tapur Edward Kim, MD 9:30 NCI-Match Barbara Conley, MD 9:50 DART Razelle Kurzrock, MD 10:10 ISpy Richard Schwab, MD 10:30 Q&A 10:40 Break 11:00 Personalized medicine for GI malignancies: Andrew Hendifar, MD Harnessing Her2/Neu, BRAF and MSI 11:40 Q&A 11:50 New therapeutic approaches for melanoma Omid Hamid, MD 12:10 P.M. Q&A 12:30 Lunch

CO-CHAIRS: Barry Rosenbloom, MD and Lawrence Piro, MD 1:30 KEYNOTE ADDRESS: T-cell therapeutics (CME credit will not be provided for this talk) David Chang, MD, PhD 2:20 Q&A 2:30 Updates in new therapeutics for hematological malignancies Michael Lill, MD 2:50 Q&A 3:00 Break 3:15 Fenmore Lecture: Head and neck cancer updates Ezra Cohen, MD 3:45 Q&A 3:55 HPV-related malignancies Mark Goodman, MD, PhD 4:15 Q&A 4:20 Integration of immune therapies in the treatment Heather McArthur, MD, PhD of breast cancer 4:40 Q&A 4:45 P.M. Adjourn

REGISTRATION 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine FRIDAY-SATURDAY, NOVEMBER 3-4, 2017 REGISTRATION FEES PHYSICIAN ALLIED HEALTH *RESIDENT/ INDUSTRY PROFESSIONAL FELLOW Received by October 17, 2016 $155 $85 free $200 Received after October 17, 2016 $195 $95 free $225 *Residents/Fellows are eligible to attend for a reduced registration fee. In order to receive this reduced fee, please send the written proof of residency (e.g., letter from Program Director) along with your completed registration form, or upload the written proof of residency online. REGISTRATION METHODS: ONLINE registration: cedars-sinai.edu/oncologycme MAIL form to: Office of Continuing Medical Education Attn: Registration 8797 Beverly Blvd., Suite 250 90048 FAX form to: 310-423-8596 For additional course or registration information, call 310-423-5548. Please print clearly LAST NAME FIRST NAME DEGREE SPECIALTY ADDRESS CITY STATE ZIP PHONE FAX EMAIL * An email address is required to register for the conference. CHECK ENCLOSED PAYABLE TO CSMC FOR $ PLEASE CHARGE MY CREDIT CARD VISA MASTERCARD AMEX FOR $ CC NUMBER CCV EXP DATE / AUTHORIZED SIGNATURE HOW DID YOU LEARN ABOUT THIS CME ACTIVITY? Brochure/Other Printed Materials Cedars-Sinai Website Email Internet Search Colleague Past Participant Internal Cedars-Sinai Communication Other REFUND POLICY All cancellations must be submitted in writing, and refunds will be subject to a $50 administrative charge. No refunds will be given after October 25, 2017. Please e-mail cancellation requests to cme@cshs.org. If you do not receive confirmation of your cancellation via e-mail, please call 310-423-5548. CANCELLATION POLICY Cedars-Sinai reserves the right to cancel or reschedule programs due to circumstances beyond its control, or to close registration when programs are oversubscribed. Registrants are advised against purchasing nonrefundable airline tickets until they receive registration confirmation. Cedars-Sinai is not responsible for penalties incurred as a result of cancelled transportation costs.

FACULTY *Alain C. Mita, MD Course Co-Director Co-Director, Experimental Therapeutics Program Associate Professor, Department of Medicine Cedars-Sinai *Monica Mita, MD Course Co-Director Co-Director, Experimental Therapeutics Program Associate Professor, Department of Medicine Cedars-Sinai *Robert A. Figlin, MD, FACP Course Co-Director Steven Spielberg Family Chair in Hematology/Oncology Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Deputy Director, Cedars-Sinai Razelle Kurzrock, MD Course Co-Director Chief, Division of Hematology & Oncology Murray Professor of Medicine Senior Deputy Director, Clinical Science Director, Center for Personalized Cancer Therapy & Clinical Trials Office UC San Diego Moores Cancer Center La Jolla, CA Lawrence D. Piro, MD Guest Course Co-Director Hematology/Oncology President and CEO of The Angeles Clinic and Research Institute *Steven Piantadosi, MD, PhD Planning Committee Experimental Therapeutics Program Associate PHASE ONE Foundation Distinguished Chair Director, Samuel Oschin Comprehensive Cancer Institute Professor, Department of Medicine Professor, Department of Medicine *Jaime Richardson Planning Committee Clinical Research Specialist David D. Chang, MD, PhD Executive Vice President, Research & Development, Chief Medical Officer Kite Pharma Santa Monica, CA Barbara A. Conley, MD Associate Director, Cancer Diagnosis Program (CDP) Division of Cancer Treatment and Diagnosis (DCTD) National Cancer Institute Rockville, MD Morganna Freeman, DO Associate Director, Melanoma and Cutaneous Oncology Program The Angeles Clinic and Research Institute Mark Goodman, MD, PhD Faculty Associate, Center for Health Policy and Ethics Professor of Family Medicine, Creighton University School of Medicine Omaha, NE Omid Hamid, MD Chief, Translational Research and Immunotherapy Director, Melanoma Therapeutics The Angeles Clinic and Research Institute *Andrew E. Hendifar, MD, MPH Co-Director, Pancreas Oncology Gastrointestinal and Neuroendocrine Malignancies Edward S. Kim, MD Chair, Solid Tumor Oncology and Investigational Therapeutics Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute Carolinas HealthCare System Charlotte, NC Michael Lill, MD Director, Stem Cell and Bone Marrow Transplant Program Professor, Medicine *Nan Limvorasak, PharmD Clinical Pharmacist *Heather McArthur, MD, PhD Medical Director, Breast Oncology Staff Physician Division of Hematology Oncology Acting Associate Professor of Medicine * Member

*Ronald B. Natale, MD Assistant Clinical Professor, Medicine Medical Director, Clinical Lung Cancer Program Steven Shiao, MD, PhD Assistant Professor, Department of Radiation Oncology and Biomedical Sciences *Edwin M. Posadas, MD Co-Medical Director, Urologic Oncology Center Clinical Director, Genitourinary Medical Oncology Program Assistant Professor, Medicine Diane Simeone, MD Greenfield Endowed Professor of Surgery and Physiology Division Chief of HPB and Advanced GI Surgery University of Michigan Medical Center Co-Director, GI Oncology Program University of Michigan Comprehensive Cancer Center Ann Arbor, MI Barry Rosenbloom, MD Partner, Tower Hematology Oncology Medical Group Attending Staff, Department of Medicine VISITING FENMORE LECTURER Ezra Cohen, MD Associate Director, Moores Cancer Center Professor of Medicine University of California, San Diego La Jolla, CA Leanne Sakamoto, PharmD Manager Outpatient Cancer Centers Richard B. Schwab, MD Associate Clinical Professor of Medicine Associate Team Leader, Comprehensive Breast Health Center Clinic Medical Director UC San Diego Moores Cancer Center La Jolla, CA VISITING REDLICH LECTURER Edward S. Kim, MD Chair, Solid Tumor Oncology and Investigational Therapeutics Donald S. Kim Distinguished Chair for Cancer Research Levine Cancer Institute Carolinas HealthCare System Charlotte, NC * Member ACTIVITY DETAILS CONFERENCE LOCATION Harvey Morse Conference Center Plaza Level, South Tower 8701 Gracie Allen Drive 90048 PARKING Self-parking is available in the visitor parking lots P1, P2 (George Burns Road) or P4 (Sherbourne Drive). HOTEL ACCOMMODATIONS For a detailed list of hotels convenient to the medical center, please visit cedars-sinai.edu/visitors, select Lodging, Dining, Services from the bottom of the page, continue to Where to Stay and select Find Lodging. When making reservations at any of these hotels, please be sure to mention that you are attending a conference at Cedars-Sinai to ensure you receive the best current reservation rate.

8797 Beverly Blvd., Suite 250 90048 Register now for: 6th Annual Experimental Therapeutics in Oncology: The Road to Personalized Medicine FRIDAY-SATURDAY, NOVEMBER 3-4, 2017 CEDARS-SINAI EXPLORE NEW AGENTS IN: Breast Cancer Head and Neck Cancers GI Malignancies T-Cell Therapeutics Earn up to 8.5 AMA PRA Category 1 Credits NON-PROFIT ORG. U.S. POSTAGE PAID Permit #22328